Cytoreductive Surgery Associated with Intraperitoneal Chemotherapy: A Nine-Year Retrospective Study of a Single-Center Moroccan Experience

Objective This study aimed to retrospectively evaluate the intraoperative management and postoperative outcomes of patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) over a nine-year period. Additionally, it provides an overview of morbidity and mortality rates. Methods Data from patients who underwent CRS/HIPEC between January 2014 and December 2022 were retrospectively analyzed. Patient demographics, clinical and pathological profiles, postoperative complications, and mortality outcomes were analyzed. Results A total of 32 patients were included in the study, with the majority being women (81.25%), with a mean age of 54.4 years. The most common comorbidities were diabetes (53.13%) and hypertension (50%). The primary indications for CRS/HIPEC were ovarian cancer (54%) and pseudomyxoma peritonei (23%). Intraoperative complications, mainly bleeding with hemodynamic collapse and hyperthermia, occurred in 20% of the patients. Postoperative complications, including hematological, metabolic, and infectious complications, were observed in 38% of the patients. The three-year mortality rate was 9.4%, corresponding to three patients. Conclusion These findings highlight the importance of thorough assessment and management of complications, as well as long-term outcomes, in patients undergoing CRS/HIPEC.